Related Experiment Video
Updated: Jan 18, 2026
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation
H M Davis1, D C Carpenter, J M Stahl
1SmithKline Beecham Pharmaceuticals, Pharmacodynamics and Exploratory Research Laboratory, Clinical Pharmacology Unit, Presbyterian Medical Center, Philadelphia, PA 19104, USA. hughdavis-1@sbphrd.com
Abstract:
A method has been developed for the direct quantification of the CD11b integrin on granulocytes by flow cytometric analysis of whole blood specimens following either LTB(4) or lipopolysaccharide (LPS) stimulation. This method has utility in evaluating the pharmacodynamic action of either LTB(4) receptor antagonists or immune cell modulators in effecting CD11b integrin expression and granulocyte activation in human subjects administered such drugs. Previous studies using CD11b as a biomarker of granulocyte activation have faltered because of the difficulty in controlling the activation state of the granulocyte following removal of blood from subjects. The present study has made use of a newly validated method using either LTB(4) or LPS to stimulate CD11b expression on granulocytes and has been used, as one measure, in the evaluation of LPS activity when administered to normal human volunteers.
